English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 45422/58598 (78%)
造訪人次 : 2516901      線上人數 : 199
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/5248


    題名: 人類尿液萃取物對於大鼠神經膠質瘤細胞株之生長抑制與凋亡作用
    The Growth-Inhibitory and Apoptotic Effects of Human Urine Extracts on C6 Rat Glioma Cells
    作者: 宋奉宜
    Fon-Yi Sung
    貢獻者: 醫學研究所
    關鍵詞: 神經膠質瘤細胞株
    神經膠質瘤
    尿療法
    大鼠
    細胞凋亡
    細胞分化
    C6 glioma cell
    urine extract
    rat
    apoptosis
    differentiation
    日期: 2000
    上傳時間: 2009-09-11 15:28:07 (UTC+8)
    摘要: 傳統的西方醫學認為癌細胞的發生,主要肇因於基因突變導致癌基因的活化或是抑癌基因的去活化。對於癌症治療的主流意見則多半傾向於以外科手術的方式完全清除病灶。毀滅性的細胞毒性療法,如化學治療,放射治療或是免疫療法等,均是朝向對癌細胞「毋枉毋縱,斬草除根」的治療方向作努力。
    另一方面,由於分化促進劑或凋亡促進劑的發現,有些學者隨之提出輔助的癌化機轉假說。他們認為細胞的癌化或正常分化等行為之改變,也可能是在DNA轉錄成RNA,或RNA製造蛋白質產物的過程中,產生了阻斷或變異的結果。此一假說也提供了臨床治療上的另一思考方向。
    自從1976年,美國德州休士頓Stanislaw Burzynski醫師發表了第一篇人尿萃取物與癌症治療觀念的文獻以來,目前已經證實,人尿萃取物確實可以抑制某些人類癌細胞株培養菌落的形成,或者是促進分化現象。對於致癌基因或p53、pRb及TGF-β之表現與作用以及癌症轉移所需要的細胞間黏著分子ICAM-I,也有不同程度的影響。在與其他抗癌藥物的協同作用方面,研究結果也顯示人尿萃取物可以增進其他抗癌藥物之抗癌效果。
    本文嘗試針對人尿萃取物所造成的分化誘導現象,作定性與定量方面的確認。在藥物導致細胞型態改變的觀察過程中,我們發現神經膠質瘤細胞有因為人尿萃取物而逐漸改變外表型態的現象。經過抑制生長試驗與分化標誌麩胺酸生成酵素定量等試驗之後,我們相信人尿萃取物確實可以引起神經膠質瘤細胞的生長抑制與分化現象。利用染色體片斷階梯檢測法測試人尿萃取物處理後的細胞,並沒有出現明顯的染色體片斷化現象。流式細胞儀針對處理後的細胞做細胞週期檢驗,則發現G0/G1期之細胞比率增加,SubG1期細胞比例則沒有明顯變化,顯示細胞應該是趨向分化狀態,並且沒有可見的細胞凋亡產生。最後的細胞螢光凋亡染色步驟,也顯示出人尿萃取物並不會造成細胞趨向凋亡過程。
    因此我們認為,人尿萃取物確實可以引起大鼠神經膠質瘤細胞的生長抑制現象,且該現象之產生應該是細胞逐漸趨向分化的結果,詳細機轉則尚待查明。
    In traditional western medicine field, we have proposed thoughts about the mechanisms and therapies of cancer. Because the difficulty of altering genes, most therapeutics'' suggests for cancer are radical excision as early as possible, followed by cytotoxic drugs or radiotherapy or immune therapy to eradicate the residues, if any.
    On the other hand, the existence of differentiative or apoptotic inducers showed us the other face of cancer research. A new though was given as "epigenetic effect" which means the material may cause some changes without altering the gene or DNA level, but on the RNA level or even later, protein level. By changing the RNA or protein product as new methylation pathway, the cell behaviors such as un-limited proliferation and phenotypic changes may stop. These gave us new approaches for cancer treatment, especially on terminal patients.
    Dr. Stanislaw Burzynski found that plenty of mall peptides naturally existed in human urine might play the role of cell growth inhibitor on multiple cultured cancer cell line in 1976. Since then, continuous studies revealed the possible inhibitory effects and cell types could be treated. Combinative therapeutic protocols also were presented as well.
    Our study tried to demonstrate the effect of human urine extracts as differentiation induction on C6 glioma cells, and also the growth inhibitory phenomenon we found. By observing drug-induced phenotypic change, growth inhibitory test and quantitative assay of differentiation marker, glutamine synthetase, we believe that the drug does induce growth inhibitory and differential effects on C6 glioma cells. By DNA ladder test and Hoechst 33258 florescence apoptotic examination, we concluded that the drug would not cause any apoptotic effect on the cell. Flow-cytometry of primary cell cycle observation also confirmed the result with extra evidences on differentiation side.
    The conclusions are the human urinary extracts, CDA-II, may cause cancer cell differentiation without apoptotic effect, and mechanisms to be determined.
    資料類型: thesis
    顯示於類別:[醫學科學研究所] 博碩士論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    摘要.doc33KbMicrosoft Word128檢視/開啟
    摘要.pdf78KbAdobe PDF141檢視/開啟
    摘要.ppt98KbMicrosoft Powerpoint125檢視/開啟
    摘要.ps504KbPostscript78檢視/開啟


    在TMUIR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    著作權聲明 Copyright Notice
    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏,包含體系內各式學術著作及學術產出。秉持開放取用的精神,提供使用者進行資料檢索、下載與取用,惟仍請適度、合理地於合法範圍內使用本平台之內容,以尊重著作權人之權益。商業上之利用,請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台,視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例,並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者,煩請權利人通知本平台維護人員([email protected]),將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋